Werfen, a global developer, manufacturer and distributor of specialised diagnostic instruments, is to acquire Immucor, Inc, a US-based specialist in transfusion and transplant in vitro diagnostics, from private equity firm TPG for approximately $2bn.
The acquisition, which is subject to customary regulatory approvals, is being funded with a mix of cash on hand and new senior credit facilities. Werfen does not expect the transaction to impact its investment grade rating from Standard & Poor’s.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
TPG acquired Immucor in July 2011 in a $1.97 billion deal, and has subsequently made multiple add-on acquisitions including Sentilus Inc and Organ-i Inc.
Upon completion of this acquisition, and based on 2021 figures, Werfen will surpass €2.2 billion in revenue, with seven technology centers, close to 7,000 employees worldwide, and a direct presence in 30 countries and more than 100 territories through distributors.
Werfen was advised by Barclays and Milbank LLP. BBVA, BNP Paribas, CaixaBank and HSBC Holding plc provided commitments for the new senior credit facilities. The sellers and Immucor were advised by Evercore and Ropes & Gray LLP.
Source: Private Equity Wire
Can’t stop reading? Read more
Mutares exits €100m logistics platform inTime Group to Tawin Holdings
Mutares exits €100m logistics platform inTime Group to Tawin Holdings Mutares has agreed to sell...
KKR taps banks for $500m financing to back $1.3bn XCL deal
KKR taps banks for $500m financing to back $1.3bn XCL deal KKR is seeking a $500m loan to support...
Amundi, KKR and Temasek unit compete for UOB asset management arm
Amundi, KKR and Temasek unit compete for UOB asset management arm Amundi, KKR, and Seviora are...